Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - The lancet …, 2014 - thelancet.com
Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …
被引用次数：320 相关文章

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - The Lancet …, 2014 - europepmc.org
Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - The Lancet …, 2014 - Elsevier
Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …
[PDF] academia.edu

[PDF][PDF] Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - Lancet Oncol, 2014 - academia.edu
BackgroundEvidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - Lancet …, 2014 - discovery.dundee.ac.uk
BACKGROUND: Evidence is scarce for the effectiveness of therapies for oesophageal
cancer progressing after chemotherapy, and no randomised trials have been reported. We …

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - The Lancet …, 2014 - clok.uclan.ac.uk
Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby… - The Lancet …, 2014 - pureportal.coventry.ac.uk
Background: Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

[引用][C] Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - The Lancet …, 2014 - investigacion.usc.gal
Background: Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

[引用][C] Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - The Lancet …, 2014 - cir.nii.ac.jp
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3,
multicentre, double-blind, placebo-controlled randomised trial | CiNii Research CiNii 国立情報学 …